KEROS THERAPEUTICS INC (KROS) Stock News

Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)

Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on stock movements.

Get insights into the top gainers and losers of Wednesday's pre-market session.

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS

Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS

Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud

Notable Thursday Option Activity: KROS, AMKR, SQ

RSI Alert: Keros Therapeutics (KROS) Now Oversold

Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study

The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug.

Keros Plunges After Dosing Halted in Lung Drug Trial on Safety

Keros Therapeutics Inc. shares plunged after the biotech company halted dosing for some patients in a mid-stage trial of its lung disorder drug over side effect concerns.

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros...

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden,...

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...

KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024

KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Keros Therapeutics (NASDAQ:KROS) just reported results for the second quarter o...

Keros Therapeutics Reports Second Quarter 2024 Financial Results

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...